Computer-aided discovery of novel non-peptide inhibitors against amyloid-beta (Aβ) peptide aggregation for treating Alzheimer's disease

Molecular Simulation

Volumn 41, Issue 8, 2015, Pages 622-632

  Zhou, Zheng Li ^a   Ho, Yih ^b   Liu, Hsuan Liang ^a   Elumalai, Pavadai ^c   Chen, Wei Hsi ^d  

^a NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

Alzheimer's disease; amyloid beta; non peptide inhibitor; structure based pharmacophore; virtual screening

Indexed keywords

DIAGNOSIS; GLYCOPROTEINS; HYDROGEN BONDS; MOLECULAR DYNAMICS; MOLECULAR MODELING; NEURODEGENERATIVE DISEASES; PHARMACODYNAMICS; QUERY PROCESSING;

ALZHEIMER'S DISEASE; AMYLOID BETAS; PEPTIDE INHIBITORS; PHARMACOPHORES; VIRTUAL SCREENING;

PEPTIDES;

EID: 84925643657     PISSN: 08927022     EISSN: 10290435     Source Type: Journal    
DOI: 10.1080/08927022.2014.910600     Document Type: Article

References (55)

1. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer's 1907 paper, 'Uber eine eigenartige Erkankung der Hirnrinde'. Clin Anat. 1995;8:429-431.
2. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci. 2000;924:17-25.
3. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:53-356.
4. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791-1800.
5. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741-766.
6. Higuchi M, Iwata N, Saido TC. Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions. Biochim Biophys Acta. 2005;1751:60-67.
7. Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 1996;16:921-932.
8. Alvarez A, Alarcon R, Opazo C, Campos EO, Munoz FJ, Calderon FH, Dajas F, Gentry MK, Doctor BP, De Mello FG, Inestrosa NC. Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J Neurosci. 1998;18:3213-3223.
9. Munoz FJ, Inestrosa NC. Neurotoxicity of acetylcholinesterase-amyloid-b-peptide aggregates is dependent on the type Ab-peptide and the AChE concentration present in the complexes. FEBS Lett. 1999;450:205-209.
10. Benzinger TL, Gregory DM, Burkoth TS, Miller-Auer H, Lynn DG, Botto RE, Meredith SC. Two-dimensional structure of beta-amyloid (10-35) fibrils. Biochemistry. 2000;39:3491-3499.
11. Petkova AT, Buntkowsky G, Dyda F, Leapman RD, Yau WM, Tycko R. Solid state NMR reveals a pH-dependent antiparallel betasheet registry in fibrils formed by a beta-amyloid peptide. J Mol Biol. 2004;335:247-260.
12. Petkova AT, Yau WM, Tycko R. Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils. Biochemistry. 2006;45:498-512.
13. Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Dobeli H, Schubert D, Riek R. 3D structure of Alzheimer's amyloid-beta (1-42) fibrils. Proc Natl Acad Sci U S A. 2005;102:17342-17347.
14. Tjernberg LO, Naslund J, Lindqvist F, Johansson J, Karlstrom AR, Thyberg J, Terenius L, Nordstedt C. Arrest of amyloid fibril formation by a pentapeptide ligand. J Biol Chem. 1996;271:8545-8548.
15. Soto C, Kindy MS, Baumann M, Frangione B. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun. 1996;226:672-680.
16. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castaño EM, Frangione B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nat Med. 1998;4:822-826.
17. Adessi C, Frossard MJ, Boissard C, Fraga S, Bieler S, Ruckle T, Vilbois F, Robinson SM, Mutter M, Banks WA, Soto C. Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J Biol Chem. 2003;278:13905-13911.
18. Hetenyi C, Szabo Z, Klement E, Datki Z, Kortvelyesi T, Zarandi M, Penke B. Pentapeptide amides interfere with the aggregation of beta-amyloid peptide of Alzheimer's disease. Biochem Biophys Res Commun. 2002;292:931-936.
19. Liu W, Crocker E, Zhang WY, Elliott JL, Luy B, Li H, Aimoto S, Smith SO. Structural role of glycine in amyloid fibrils formed from transmembrane alpha-helices. Biochemistry. 2005;44:3591-3597.
20. Eskici G, Gur M. Computational design of new peptide inhibitors for amyloid beta (Ab) aggregation in Alzheimer's disease. Application of a novel methodology. PLoS One. 2013;8 (e66178):1-7.
21. Ren H, Nagai Y, Tucker T, Strittmatter WJ, Burke JR. Amino acid sequence requirements of peptides that inhibit polyglutamine-protein aggregation and cell death. Biochem Biophys Res Commun. 2000;288:703-710.
22. Kapurniotu A, Schmauder A, Tenidis K. Structure-based design and study of non-amyloidogenic, double N-methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity. J Mol Biol. 2002;315:339-350.
23. Permanne B, Adessi C, Saborio GP, Fraga S, Frossard MJ, Van Dorpe J, Dewachter I, Banks WA, Van Leuven F, Soto C. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J. 2002;16:860-862.
24. NagaiY N, Fujikake N, Ohno K, Higashiyama H, Popiel HA, Rahadian J, Yamaguchi M, Strittmatter WJ, Burke JR, Toda T. Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila. Hum Mol Genet. 2003;12:1253-1259.
25. Kaidanovich-Beilin O, Eldar-Finkelman H. Peptides targeting protein kinases: strategies and implications. Physiology. 2006;21:411-418.
26. Xu W, Chen G, Liew OW, Zuo Z. Novel non-peptide beta-secretase inhibitors derived from structure-based virtual screening and bioassay. Bioorg Med Chem Lett. 2009;15:3188-3192.
27. Huang D, Lüthi U, Kolb P, Edler K, Cecchini M, Audetat S, Barberis A, Caflisch A. Discovery of cell-permeable non-peptide inhibitors of beta-secretase by high-throughput docking and continuum electrostatics calculations. J Med Chem. 2005;11:5108-5111.
28. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Protein aggregation and neurodegenerative disease. Nat Med. 2004;10:S10-S17.
29. Wan J, Morin P, Wang W, Kollman PA. Use of MM-PBSA in reproducing the binding free energies to HIV-1 RTof TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. J Am Chem Soc. 2011;123:5221-5230.
30. Jagota S, Rajadas J. The role of Pro, Gly Lys, and Arg containing peptides on amyloid-beta aggregation. Int J Pept Res Ther. 2011;18:53-61.
31. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The protein data bank. Nucleic Acids Res. 2000;28:235-242.
32. Brooks BR, Bruccoleri RE, Olafson BD, Swaminathan S, Karplus M, States DJ, Swaminathan S, Karplus M. CHARMM. A program for macromolecular energy, minimization and dynamic calculations. J Comput Chem. 1983;4:187-217.
33. Zhao JH, Liu HL, Elumalai P, Chen WH, Men LC, Liu KT. Molecular modeling to investigate the binding of Congo red toward GNNQQNY protofibril and in silico virtual screening for the identification of new aggregation inhibitors. J Mol Model. 2013;19:151-162.
34. Chen R, Mintseris J, Janin J, Weng Z. A protein-protein docking benchmark. Proteins. 2003;52:88-91.
35. Li L, Chen R, Weng Z. RDOCK: refinement of rigid-body protein docking predictions. Proteins. 2003;53:693-707.
36. Wu G, Robertson DH, Brooks CL 3rd, Vieth M. Detailed analysis of grid-based molecular docking. A case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem. 2003;24:1549-1562.
37. Tsai HH, Zanuy D, Haspel N, Gunasekaran K, Ma B, Tsai CJ, Nussinov R. The stability and dynamics of the human calcitonin amyloid peptide DFNKF. Biophys J. 2004;87:146-158.
38. Marcou G, Rognan D. Optimizing fragment and scaffold docking by use of molecular interaction fingerprints. J Chem Inf Model. 2007;47:195-207.
39. Krammer A, Kirchhoff PD, Jiang X, Venkatachalam CM, Waldman M. LigScore. A novel scoring function for predicting binding affinities. J Mol Graph Model. 2005;23:395-407.
40. Daniel EO, editor. Amyloid fibrils and prefibrillar aggregates: molecular and biological properties. Vol. 16. Weinheim: Wiley; 2013. p. 345-363.
41. Hawkes CA, Ng V, McLaurin J. Small molecule inhibitors of Abaggregation and neurotoxicity. Drug Dev Res. 2009;70:111-124.
42. Chen D, Martin ZS, Soto C, Schein CH. Computational selection of inhibitors of Abeta aggregation and neuronal toxicity. Bioorg Med Chem. 2009;17:5189-5197.
43. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3-26.
44. Van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise. Nat Rev Drug Discov. 2003;2:192-204.
45. Ajay D, Sobhia ME. Identification of novel, less toxic PTP-LAR inhibitors using in silico strategies: pharmacophore modeling, SADMET-based virtual screening and docking. J Mol Model. 2012;18:187-201.
46. Boda K, Seidel T, Gasteiger J. Structure and reaction based evaluation of synthetic a accessibility. J Comput Aided Mol Des. 2007;21:311-325.
47. Wagner AB. SciFinder Scholar 2006. An empirical analysis of research topic query processing. J Chem Inf Model. 2006;46:767-774.
48. Wang Y, Bolton E, Dracheva S, Karapetyan K, Shoemaker BA, Suzek TO, Wang J, Xiao J, Zhang J, Bryant SH. An overview of the PubChem BioAssay resource. Nucleic Acids Res. 2010;38: D255-D266.
49. Hochdorffer K, März-Berberich J, Nagel-Steger L, Epple M, Meyer-Zaika W, Horn AH, Sticht H, Sinha S, Bitan G, Schrader T. Rational design of b-sheet ligands against Ab42-induced toxicity. J Am Chem Soc. 2011;133:4348-4358.
50. Chini MG, Scrima M, D'Ursi AM, Bifulco G. Fibril aggregation inhibitory activity of the beta-sheet breaker peptides. A molecular docking approach. J Pept Sci. 2009;15:229-234.
51. Kassler K, Horn AH, Sticht H. Effect of pathogenic mutations on the structure and dynamics of Alzheimer's abeta 42-amyloid oligomers. J Mol Model. 2010;16:1011-1020.
52. Ni CL, Shi HP, Yu HM, Chang YC, Chen YR. Folding stability of amyloid-beta 40 monomer is an important determinant of the nucleation kinetics in fibrillization. FASEB J. 2011;25:1390-1401.
53. Zhu X, Bora RP, Barman A, Singh R, Prabhakar R. Dimerization of the full-length Alzheimer amyloid beta-peptide (Abeta42) in explicit aqueous solution. A molecular dynamics study. J Phys Chem B. 2012;116:4405-4416.
54. He S, Wu Y, Yu D, Lai L. Microsomal prostaglandin E synthase-1 exhibits one-third-of-the-sites reactivity. Biochem J. 2011; 440:13-21.
55. Kabsch W, Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers. 1983;22:2577-2637.